Ceftobiprole: Difference between revisions
From IDWiki
Content deleted Content added
No edit summary |
No edit summary |
||
| Line 17: | Line 17: | ||
==Dosing== |
==Dosing== |
||
* |
*Usual dose: 500 mg IV q8h over 2 hours |
||
*[[Staphylococcus aureus bacteremia]]: 500 mg IV q6h for 8 days followed by q8h |
|||
=== Renal Dosing === |
=== Renal Dosing === |
||
Latest revision as of 19:45, 15 December 2025
Background
Mechanism of Action
- Binds to and inhibits PBP-2a on MRSA
- Binds to and inhibits PBP-2x on penicillin-resistant Streptococcus pneumoniae
Spectrum of Activity
- Active against MRSA, ampicillin-susceptible Enterococcus, and penicillin-resistant Streptococcus pneumoniae, as well as aerobic Gram-negative bacteria similar to other third-generation cephalosporins
- Not active against Pseudomonas, ESBL-producers, or AmpC-producers
Pharmacokinetics and Pharmacodynamics
- Crosses into CSF adequately
Dosing
- Usual dose: 500 mg IV q8h over 2 hours
- Staphylococcus aureus bacteremia: 500 mg IV q6h for 8 days followed by q8h
Renal Dosing
- Required if CrCl <50 mL/min
Safety
Adverse Drug Reactions
- Nausea, diarrhea, neutropenia (4%), dysgeusia
